Ewing's sarcoma of the pelvis traditionally has been a difficult problem in orthopaedic oncology. Multiple studies have had inferior outcomes when compared with outcomes of patients with similar stage disease involving only the extremities. A major reason for this discrepancy is the difficulty associated with resection and reconstruction of pelvic tumors. Often the tumors are deemed nonresectable and are treated with chemotherapy and radiation or radiation alone. Patients treated in this manner have lower 5-year survival rates, higher local recurrence rates, and multiple long-term complications. The case of a 4-year-old girl with Ewing's sarcoma of the left hemi-pelvis is reported. Combined with adjuvant chemotherapy, this patient was treated with resection followed by osteoarticular allograft reconstruction. At 2 years followup, the patient was disease-free with an excellent functional outcome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00003086-200402000-00024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary Visceral Ewing Sarcoma (Gastric and Bladder) with KIT Expression: A Report of Two Patients and a Differential Diagnostic Approach.
Int J Surg Pathol
January 2025
Pathology Department, University of Valencia, Valencia, Spain.
Extra-skeletal Ewing sarcoma is a rare tumor, most commonly occurring in the paravertebral region, extremities, retroperitoneum, and very rarely in visceral locations. We present two primary visceral Ewing sarcomas confirmed at the molecular level: one located in the stomach and the other in the bladder. Both tumors demonstrated strong and diffuse membranous CD99 expression, accompanied by variable KIT immunoreactivity.
View Article and Find Full Text PDFInternational benchmarking of stage at diagnosis for six childhood solid tumours (the BENCHISTA project): a population-based, retrospective cohort study.
Lancet Child Adolesc Health
February 2025
Developmental Biology and Cancer Research & Teaching Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK. Electronic address:
Background: International variation in childhood cancer survival might be explained by differences in stage at diagnosis, among other factors. As part of the BENCHISTA project, we aimed to assess geographical variation in tumour stage at diagnosis through the application, by population-based cancer registries working with clinicians, of the international consensus Toronto Childhood Cancer Stage Guidelines.
Methods: This population-based, retrospective cohort study involved 67 cancer registries from 23 European countries, Australia, Brazil, Japan, and Canada.
Safety and Tolerability of Interval Compressed Chemotherapy Schedule in Children Receiving Treatment for Ewing Sarcoma: A Real-world Experience From India.
J Pediatr Hematol Oncol
January 2025
MVR Cancer Centre and Research Institute, Calicut, Kerala, India.
Background And Aims: Chemotherapy with alternating cycles of vincristine-doxorubicin-cyclophosphamide and ifosfamide-etoposide, along with primary tumor treatment with surgery or radiotherapy or both, constitute the usual treatment of Ewing sarcoma. The AEWS0031 study demonstrated survival benefits after interval-compressed chemotherapy without significant toxicity. The aim of this study was to assess the tolerability of dose-intensified chemotherapy in developing countries like India.
View Article and Find Full Text PDFBone sarcomas and cancer predisposition syndromes.
Bull Cancer
January 2025
Department of Paediatric Oncology, Institut d'Haematologie et d'Oncologie Pédiatrique, Centre Léon-Bérard, Lyon, France. Electronic address:
Bone sarcomas, constituting less than 1% of malignant neoplasms across all age groups, are rare tumours possibly associated with genetic susceptibility syndromes. This review aims to provide recommendations for the detection of cancer predisposition syndromes associated with bone sarcomas and managing affected patients. Recommendations were formulated by a multidisciplinary working and reviewing group from GROUPOS and SFCE oncogenetic's group, including geneticists, oncologists, and radiologists.
View Article and Find Full Text PDFIncidence and survival of European adolescents and young adults diagnosed with sarcomas: EUROCARE-6 results.
Eur J Cancer
January 2025
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Background: Epidemiological data for sarcoma in adolescents and young adults (AYAs) and across age groups are limited. We aim to: 1) update sarcoma incidence, survival, and changes over time in European AYAs; 2) provide an updated comparison of sarcoma survival in AYAs versus children and mature adults.
Methods: We calculated crude incidence rates (IR) per 100,000 European population per year from 2006 to 2013.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!